Introduction
Activated Factor XIII (fibrin stabilizing factor) is a transamidase that participates in the final event of blood coagulation (1) . It covalently crosslinks fibrin monomers into stable fibrin clot by the formation of e-(y-glutamyl) lysyl bonds in fibrin. Patients with deficiency of this clotting factor may have as manifestations excessive bleeding, defective wound healing, and fetal wastage (1) . Plasma Factor XIII, with a mol wt of 320,000, is a tetramer composed of two A and two B subunits (1) (2) (3) (4) . The A subunit, with a mol wt of 75,000, is the zymogen that possesses the Factor XIII enzymatic activity after activation by thrombin in the presence of calcium ions. The B subunit, with a mol wt of 80,000, functions as a carrier for the A subunit. Both platelets (2) (3) (4) (5) (6) (7) (8) and monocytes (9, 10) have been found to contain Factor XIII in their cytoplasm, but only the 75,000 mol wt A subunits are present. The Factor XIII A subunits (FXIIIA)' in platelets, monocytes, and plasma are biochemically, functionally, and immunologically similar (2) (3) (4) (5) (6) (7) (8) (9) (10) .
It has been estimated that only about half of the total circulating FXIIIA is present in plasma (6, 1 1); the other half is contained in the blood cells. Hemopoiesis has been suggested as a source of FXIIIA in these components, but the extent of this contribution, especially to plasma, has not been conclusively demonstrated. Polymorphism of FXIIIA has been observed (12). Using an agarose gel electrophoresis system, three common phenotypes have been described. Phenotype 1-1 consists of a single fast-moving band; 2-2 consists of a single slow-moving band; and 1-2 consists of both the fast-and slowmoving bands, plus an intermediate moving band. In this study we used the FXIIIA polymorphism to follow the contribution of hemopoiesis to plasma and cellular FXIIIA in patients after bone marrow transplantation.
Methods
Patients. Patients with aplastic anemia or hematologic malignancy accepted to the bone marrow transplantation program at the University of Calgary were studied. FXIIIA phenotypes were determined on these patients and their HLA A, B, and DR identical sibling donors. When the FXIIIA phenotypes in the recipient and donor pair were different, the plasma and cellular FXIIIA phenotypes of the recipient patients were determined at intervals after transplantation. The transplantation protocol included conditioning therapy before infusion with 1.8-3 X 108 donor marrow nucleated cells per kilogram recipient body weight. The conditioning therapy was intravenous cyclophosphamide (120 mg/kg) plus various combinations of total body irradiation, intravenous cytosine arabinoside, and oral busulfan according to the underlying disorders. A combination of intravenous methotrexate and cyclosporin A was used for prophylaxis of graft vs. host disease.
Plasma and cell specimens. Venous blood was collected in vacutainer tubes containing K3EDTA (10.5 mg/7 ml blood; Becton Dickinson, Mississauga, ON). Plasma and platelets washed twice with saline were prepared from the EDTA anticoagulated blood according to the methods described by Board et al. (12) . The separated platelets contained < 103 total white cells/106 platelets. Monocytes were separated by density gradient centrifugation in colloidal silica supplied commercially (Sepracell-MN; Sepratech Corp., Oklahoma City, OK), and washed twice in PBS (0.009 M phosphate, 0.003 M KCI, 0.14 M NaCl, pH 7.4) containing 0.1% BSA according to the manufacturer's instructions. The recovery of monocytes was 88±9.7%, with lymphocytes as the major contaminants and no appreciable contamination with platelets (< 102 platelets/106 monocytes) and PMN. All plasma aliquots and pellets of platelets and monocytes were frozen at -70°C.
Frozen cells were thawed and used only once.
Factor XIII studies. FXIIIA phenotype determination was performed according to the method of Graham et al. (13) . The FXIIIA variants were separated by agarose gel (Seakem ME; FMC Corporation, Rockland, ME) electrophoresis and visualized and photographed with ultraviolet light illumination after incorporation of monodansyl cadaverine to casein by the thrombin-and Ca++-dependent transglutaminase activity of FXIIIA. 5-Ml samples were applied for electrophoresis. Plasma samples were applied after dilutions with TEB buffer (0.18 M Tris, 0.04 M Na2EDTA, 0.1 M boric acid, pH 8.6). Except for the titration study (see below), plasma was routinely studied at 1/4-1/8 dilution. At lower plasma dilution the bands tend to smudge. Frozen platelet or monocyte pellets separated from 7 ml blood were preincubated with 50 Ml 1% Triton X-100 in TEB buffer at room temperature for 30 min, and 5 Ml applied without further dilution.
The procedure could identify FXIIIA phenotypes at a plasma sample concentration of0.035 U/ml for phenotype 1-1 and 0.050 U/ml for phenotype 1-2. The minimal numbers of platelets and monocytes required for phenotype identification were DNA studies. DNA was extracted from peripheral blood or marrow aspirate using standard techniques (15) . DNA (2 Mg) was digested with Pst I (hMF-l) or Sin I (3HVR), separated on 1% agarose gels, alkaline blotted, and probed with the hMF-l or 3HVR probe as previously described (16, 17) . The hMF-l sequence from the D1Z2 locus of chromosome 1 recognizes complex allelic patterns that can differentiate most unrelated individuals. Within families, on the average one in four will share alleles and be identical. The 3HVR probe is on chromosome 16 and recognizes a two-allele pattern at high stringency. We Fig. 1 A shows the FXIIIA phenotype studies on patient 1, a 32-yr-old woman transplanted for acute promyelocytic leukemia in second remission. She had a FXIIIA phenotype of 1-1 (plasma, platelets, and monocytes), and her female donor had a phenotype of 1-2. After transplantation, the first study was performed on day 31 when the patient was hematologically normal with a platelet count of 171 X 109/liter and a white count of 5.4 X 109/liter with 6% monocytes, and when she had not received any blood components for 12 d. The patient had received platelets but no additional plasma after the transplantation. At this time both the platelets and monocytes had assumed the donor phenotype of 1-2, and remained phenotype 1-2 upon multiple follow-up studies over a 22-mo period. The plasma phenotype studied at intervals from days 31 to 93 continued to be that of the recipient 1-1, but changed to 1-2 when studied on day 115, and remained 1-2 thereafter. The plasma FXIIIA activity of the patient after transplantation did not vary significantly from the pretransplant level (1.09 U/ml) during the initial 100 d of follow-up.
The patient had a continuing normal peripheral blood and marrow picture, with no blood component transfusion since day 19 posttransplantation. Her red cell phenotype also changed from pretransplant group A to donor group 0 without residual group A cells. Peripheral blood cell DNA studies using hMF-1 ( Fig. 2 A) and 3'HVR ( Fig. 3 A) on day 295 posttransplantation showed a change of phenotype to one that had clear donor-specific fragments confirming marrow transplantation. However, there was a persistence of recipient-specific fragments in the peripheral blood cell DNA, indicating that there still existed a population of recipient elements. Analysis with 3'HVR suggested the chimerism was approximately equally representing donor and recipient (Fig. 3 A) .
Patient 2. Fig. 1 B shows the FXIIIA phenotype studies on patient 2, a 39-yr-old man transplanted for acute granulocytic leukemia in first remission. He had a FXIIIA phenotype of 1-2, and his male donor had a phenotype of 1-1. After transplantation, the first study was performed at day 23 when the patient had not received any blood components for 11 d, and when his platelet count was 68 X 109/liter and his white count was 2.3 X 109/liter with 51% monocytes. This patient had received platelets but no additional plasma after the transplantation. At this time the platelet and monocyte FXIIIA had assumed the donor phenotype of 1-1 and remained so upon multiple follow-up studies over a 15-mo period. The plasma FXIIIA phenotype remained 1-2 and had not changed when studied on day 233 posttransplantation. The plasma on day 288 posttransplant clearly showed a decreased intensity of the two slow-moving bands compared with the fastest-moving band. The intensity of the two slow-moving bands continued to decrease gradually, but they were still faintly visible (with an enriched fast-moving band) when the plasma from day 458 posttransplant was last studied. The plasma FXIIIA activity of the patient after transplantation dropped slightly, from 0.87 to 0.78 U/ml by day 23, and then increased gradually to 1.3 U/ml by day 77. The activity then stabilized at 0.95 U/ml from day 87 after transplantation. (Fig. 2 B) , and a change to donor red cell phenotypes.
Patient 3. Fig. 1 (Fig. 3 B) The origin of plasma FXIIIA appears to be more complex. Our study suggests that there is a definite and major contribution to plasma FXIIIA by the transplanted hemopoietic cells. This is clearly demonstrated by the complete change-over from recipient 1-1 to donor 1-2 phenotype in patient 1, and by the increasing intensity of the fastest-moving band (due to enrichment of donor phenotype 1-1) in patients 2 and 3. The hemopoietic cells' contribution to plasma FXIIIA is probably via the platelets and monocytes and/or their precursors, but we cannot conclude whether one or both of these cell lines contribute. Previous studies have shown that sickle cell disease patients with thrombocytosis may have an increased plasma concentration of FXIIIA (26), while some patients with idiopathic thrombocytopenia purpura (22) and cytopenias secondary to acute leukemia (27) had lower plasma FXIIIA levels. In experimental studies rats rendered cytopenic by cytotoxic or other agents had decreased FXIIIA levels (28) . However, these studies also showed that in long-standing severely thrombocytopenic patients the reduction of plasma FXIIIA was less than expected (22), suggesting that platelets were not the sole contributor. How platelet FXIIIA reaches the plasma is unknown as FXIIIA is not released during platelet release reaction and clot retraction (29). How monocytes would contribute to plasma levels of FXIIIA has yet to be determined, although in vitro culture studies suggest that FXIIIA is secreted into the culture media (23) .
The long time period required to change the plasma FXIIIA phenotype ofpatient 1 (between 93 and 115 d) and the inability of the plasma FXIIIA of patients 2 and 3 to change completely from recipient 1-2 to donor 1-1 phenotype by 15 and 13 mo, respectively, after transplantation also suggest that FXIIIA sources other than the donor hemopoietic cells may also be present. When a mixture of 1-1 and 1-2 plasma was studied in our FXIIIA phenotyping system, phenotype 1-2 would be expressed when the phenotype 1-2 plasma FXIIIA activity was > 0.26 (±0.03) in proportion, and phenotype 1-1 would be expressed when the phenotype 1-1 plasma FXIIIA activity was > 0.83 (±0.04) in proportion. Given an estimated FXIIIA t1/2 of 3-14 d (1) , if the donor hemopoietic cells were the sole source of plasma FXIIIA, the phenotypic change-over would have been completed in less than one tl/2 after hematologic recovery for patient 1, and within three tl/2 after hematologic recovery for patients 2 and 3. Normal peripheral white cell and platelet counts were observed by day 32 in patients 1 and 2, and by day 100 in patient 3.
Although blood chimerism demonstrated by DNA genotyping in patient 1 makes interpretation of delayed changeover of plasma FXIII phenotype impossible, chimerism is unlikely in patients 2 and 3. In patient 3 complete donor marrow engraftment was suggested by peripheral blood and marrow DNA genotyping studies, red cell phenotyping, and the cytogenetic demonstration of the disappearance of the original disease marker Philadelphia chromosome. Successful donor marrow engraftment in patient 2 was demonstrated by red cell phenotype and peripheral blood DNA genotyping studies. Although marrow DNA was not studied in patient 2, an undetected significant megakaryocyte/platelet chimerism is unlikely. In Fig. 1 B the posttransplant platelet FXIIIA was clearly a single band (donor phenotype 1-1). The concentration of this sample (150 X I05 platelets/5 pA1) was 150-fold the concentration required for phenotype identification and should have shown the extra two slower-moving bands if the recipient pretransplant platelets (with phenotype 1-2) were present at > I1/150 (0.67%) of the sample.
One possible recipient source of FXIIIA that would delay the plasma FXIIIA phenotype change after transplantation is residual recipient tissue (hepatic, splenic, and pulmonary alveolar) macrophages. These tissue cells, derived from transformed monocytes (30) (31) (32) , can apparently proliferate independently of the marrow precursors (30) , and have a longer disappearance time than circulating monocytes (31). After marrow transplantation resident recipient pulmonary alveolar macrophages could be recovered in decreasing numbers until approximately day 81 (31) . This lifespan figure of 81 d after marrow transplantation is probably applicable to other tissue macrophages, as recipient macrophages could no longer be identified in the liver of a patient who died 104 d after transplantation (32) . While these tissue macrophage sources will certainly cause a delay in plasma FXIIIA phenotype change in our patients, their lifespan is not sufficiently long to explain totally the long delay seen in patients 2 and 3, suggesting that extrahemopoietic sources may be present.
Liver has been suggested as a possible extrahemopoietic source ofplasma FXIIIA by some, but not all, studies. Patients with liver disease may have a decreased plasma FXIIIA level (27), but it is not known ifthis is secondary to a decrease in the carrier protein Factor XIII B subunits synthesized by the hepatocytes (21, 33, 34). Immunological and in vitro culture studies of hepatocytes and hepatoma cell lines have given conflicting results. Synthesis was shown by some studies (33, 34) but not by others (35, 36) . Recently, FXIIIA mRNA has been found in liver biopsy preparations by Northern blot analysis with a cloned FXIIIA gene (24) . However, a contribution of FXIIIA mRNA from macrophages in the preparation has not been definitely excluded, and a similar study by Grundmann et al. (37) failed to identify FXIIIA mRNA in the liver.
Our study, therefore, allows us to identify the transplanted hemopoietic cells as a source of plasma FXIIIA; however, the data do not allow us to conclude whether the contribution is from platelets, monocytes, or both. We also conclude that there are additional sources of plasma FXIIIA. One source could be residual recipient tissue macrophages, also of hemopoietic origin, but additional extrahemopoietic sources are distinct possibilities. Identification of the exact tissue site(s) will require further study. A marrow transplantation model was also used by Wolpl et al. (21) to study plasma FXIIIA origin, but the study was incomplete for interpretation. The study demonstrated that the plasma FXIIIA of two patients with phenotype 1-1 and one patient with phenotype 2-2 all changed to the donor phenotype 1-2 in 11, 8, and 6 d, respectively, after the last platelet transfusions. The relationship of this time period to the day oftransplantation was not stated, so it is not possible to assess whether other sources of plasma FXIIIA were present. Furthermore, they did not study a phenotype 1-2 (three bands) recipient transplanted with marrow from a donor with phenotype 1-1 or 2-2 (both with one band).
As suggested in our studies, transplantation of marrow from a donor with the FXIIIA phenotype consisting of one band (i.e., 1-1 or 2-2) to a recipient with the phenotype consisting ofthree bands (i.e., 1-2) requires higher proportions of donor FXIIIA (or a greater degree of recipient FXIIIA depletion) for expression of the complete change. The latter studies we have performed should, therefore, be more sensitive for detecting low levels of FXIIIA contribution by recipient sources.
Although the genes for both FXIIIA and the HLA antigens are located on chromosome 6 (12, 25, 38-40), our 40), that HLA and FXIIIA genes are not closely linked. Platelet and monocyte FXIIIA polymorphism can, therefore, be used as a marker for bone marrow engraftment in the appropriate patients. This marker has the advantage that it can be used as early as the fourth week after transplantation during early hemopoietic recovery. Our study also provides an example of how DNA genotyping can be used to follow marrow engraftment after transplantation. This technique has recently been applied for evaluation of long-term engraftment after marrow transplantation in patients with aplastic anemia (41) .
